Lower drug dose may prevent transplant complications without extra risk
NCT ID NCT07319000
First seen Jan 09, 2026 · Last updated May 12, 2026 · Updated 20 times
Summary
This study tested whether a lower dose of a drug called cyclophosphamide could prevent graft-versus-host disease (GVHD) in 35 adults receiving stem cell transplants for blood cancers or disorders. GVHD is a serious side effect where donor cells attack the patient's body. The lower dose aimed to be as effective as the standard dose while helping blood cells recover faster. The study found that the low dose kept severe GVHD rates low, similar to historical results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Universitario de Monterrey
Monterrey, 64460, Mexico
Conditions
Explore the condition pages connected to this study.